This company has been marked as potentially delisted and may not be actively trading. ERYTECH Pharma (ERYP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ERYP vs. IKT, PLX, CVM, ZIVO, IZTC, CRTX, JATT, ALVR, FNCH, and NKGNShould you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), Cortexyme (CRTX), JATT Acquisition (JATT), AlloVir (ALVR), Finch Therapeutics Group (FNCH), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector. ERYTECH Pharma vs. Its Competitors Inhibikase Therapeutics Protalix BioTherapeutics CEL-SCI ZIVO Bioscience Invizyne Technologies Cortexyme JATT Acquisition AlloVir Finch Therapeutics Group NKGen Biotech Inhibikase Therapeutics (NYSE:IKT) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Which has better earnings & valuation, IKT or ERYP? ERYTECH Pharma has higher revenue and earnings than Inhibikase Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.63ERYTECH Pharma$32.66M3.24-$240KN/AN/A Does the media prefer IKT or ERYP? In the previous week, Inhibikase Therapeutics' average media sentiment score of 0.00 equaled ERYTECH Pharma'saverage media sentiment score. Company Overall Sentiment Inhibikase Therapeutics Neutral ERYTECH Pharma Neutral Is IKT or ERYP more profitable? ERYTECH Pharma's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% ERYTECH Pharma N/A N/A N/A Do institutionals & insiders hold more shares of IKT or ERYP? 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 1.1% of ERYTECH Pharma shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 1.9% of ERYTECH Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, IKT or ERYP? Inhibikase Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.69, suggesting that its stock price is 169% more volatile than the S&P 500. Do analysts rate IKT or ERYP? Inhibikase Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 289.22%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than ERYTECH Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50ERYTECH Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryInhibikase Therapeutics and ERYTECH Pharma tied by winning 5 of the 10 factors compared between the two stocks. Get ERYTECH Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERYP vs. The Competition Export to ExcelMetricERYTECH PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.77M$290.97M$5.83B$9.92BDividend YieldN/AN/A6.70%4.51%P/E RatioN/AN/A76.2926.13Price / Sales3.24474.43529.66172.92Price / CashN/A22.4436.9959.28Price / Book3.8810.9411.486.09Net Income-$240K-$111.61M$3.29B$266.51M ERYTECH Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERYPERYTECH PharmaN/A$3.10flatN/AN/A$105.77M$32.66M0.0049IKTInhibikase Therapeutics1.5925 of 5 stars$1.75-0.9%$6.50+272.5%+21.0%$130.41MN/A-0.666PLXProtalix BioTherapeutics3.1392 of 5 stars$1.64-0.3%$15.00+817.4%+54.0%$130.36M$61.95M-12.58200Gap UpCVMCEL-SCI0.3072 of 5 stars$11.74-3.5%N/A-67.2%$80.75MN/A-24.4443Short Interest ↑ZIVOZIVO Bioscience0.0658 of 5 stars$17.00-2.9%N/A+35.0%$64.89M$15.85K-3.4810IZTCInvizyne TechnologiesN/A$9.70flatN/AN/A$60.64MN/A0.0029News CoverageGap UpCRTXCortexymeN/A$1.60flatN/A+130.7%$48.24MN/A-0.5455JATTJATT AcquisitionN/A$2.02-1.0%N/A-41.6%$34.85MN/A0.003High Trading VolumeALVRAlloVirN/A$4.00-2.0%N/A-73.7%$20.17MN/A-0.20110Gap DownHigh Trading VolumeFNCHFinch Therapeutics Group0.4778 of 5 stars$12.03-7.5%N/AN/A$19.32MN/A-1.36190Short Interest ↑NKGNNKGen BiotechN/A$0.20+50.9%N/A-81.8%$8.99MN/A-0.04N/AGap Up Related Companies and Tools Related Companies IKT Alternatives PLX Alternatives CVM Alternatives ZIVO Alternatives IZTC Alternatives CRTX Alternatives JATT Alternatives ALVR Alternatives FNCH Alternatives NKGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERYP) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share ERYTECH Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
